Vaccination Does Not Impact Long COVID Neurological Symptoms
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 15, 2025 -- Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postacute sequelae of SARS-CoV-2 infection, according to a study published online Jan. 7 in Brain Communications.
Shreya Mukherjee, from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues investigated whether vaccination prior to infection alters the subsequent neurologic postacute sequelae of SARS-CoV-2 infection (neuro-PASC). The analysis included data from 200 posthospitalization neuro-PASC (PNP) and 1,100 nonhospitalized neuro-PASC (NNP) patients evaluated at a neuro COVID-19 clinic between May 2020 and January 2023.
The researchers found that among PNP patients, 87 percent had a prevaccination infection, as did 70.7 percent of NPP patients. Breakthrough infections were associated with more frequent preexisting depression/anxiety. The three most common neurological symptoms for PNP patients were brain fog (86.5 percent), numbness/tingling (56.5 percent), and headache (56.5 percent) at an average of 10 months after symptom onset. PNP breakthrough infection was more frequently associated with anosmia. For NNP patients, the most common neurological symptoms were brain fog (83.9 percent), headache (70.9 percent), and dizziness (53.8 percent). For NNP patients with prevaccination infection, anosmia (56.6 versus 39.1 percent) and dysgeusia (53.3 versus 37.3 percent) occurred more frequently than for patients with breakthrough infection, whereas those with breakthrough infection more frequently reported dizziness (61.5 versus 50.6 percent). Impaired quality of life in cognitive, fatigue, sleep, anxiety, and depression domains were seen for all PASC patients, with no differences between prevaccination infection and breakthrough infection status.
"Taken together, these results indicate that, once PNP or NNP patients develop neuro-PASC, whether they contracted SARS-CoV-2 infection prior to, or after SARS-CoV-2 vaccination makes little difference in their clinical presentation, subjective alteration of quality of life or objective cognitive dysfunction," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Further Support and Information on COVID-19
Read this next
Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024
TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
COVID-19 Infection Linked to Accelerated Vascular Aging
MONDAY, Aug. 18, 2025 -- COVID-19 is associated with early vascular aging, as assessed by carotid-femoral pulse wave velocity (PWV), an established biomarker of large artery...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.